Skip to content

Response of patient of threatened abortion to two oral forms of progesterone

Comparison between Oral Dydrogesterone and Oral Micronized Progesterone in Threatened Abortion : A randomized controlled trial - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/075727
Enrollment
76
Registered
2024-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O00-O08- Pregnancy with abortive outcome

Interventions

Intervention1: Oral Micronized Progesterone: Oral micronized progesterone is a form of natural progesterone in the form of suspension of oil. It closely mimics the natural Progesterone, solves the pro

Sponsors

Rohilkhand Medical College and Hospital, Bareilly
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All Patients presenting with the threatened abortion of age more than or equal to 18 years with a live intrauterine gestation of less than or equal to 20 weeks confirmed by Ultrasonography.

Exclusion criteria

Exclusion criteria: - Known parental chromosomal anomaly. - Heavy bleeding per vaginum requiring surgical intervention. - Known allergy to any of the two or both the drugs. - Case of recurrent miscarriage i.e. three or more spontaneous miscarriages in the past. - Suspected or confirmed breast or genital cancer, hepatic disease or tumour.

Design outcomes

Primary

MeasureTime frame
- To compare Dydrogesterone and Oral Micronized Progesterone in Threatened Abortion - To determine the efficacy and safety of Oral dydrogesterone in threatened abortion. - To assess the efficacy and safety of Oral micronized progesterone in threatened abortion.Timepoint: Follow up visits scheduled at 7th, 14th and 21st day of prescription

Secondary

MeasureTime frame
- duration and extent of bleeding - fetomaternal outcomes. - mode of delivery and weight of the baby for health status - side effects during treatmentTimepoint: Follow up visits scheduled at 7th, 14th and 21st day of prescription

Countries

India

Contacts

Public ContactDr Shobha Mukherjee

Rohilkhand Medical College and Hospital

nikkijairath@gmail.com9665066760

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026